For publications in PubMed please go here.
For the first time in the world of medical practice, a unique method for restoration of the damaged retina in case of different diseases (such as diabetic retinopathy, innate and acquired degenerations, complicated myopia, maculopathies, chorioretinitises, burns) has been developed. The method is based on the application of a complex of bioregulators, isolated from the retina, vessels, pineal gland, thymus, or their synthetic analogues. The efficiency of this complex treatment is 95%, which is an unprecedented achievement in the field of ophthalmology. Wide application of bioregulators will contribute to the enhancement of the working capacity period, reduce the rate of disabilities, enhance quality of life of the patients. All these may positively affect social and economic aspects of the medical care system efficiency in Russia.
Peptide bioregulators promote restoration of the physiological activity of the retina in retinitis pigmentosa in older adults and in animal models. The molecular mechanism of the physiological activity of peptides is associated with their ability to epigenetically regulate the synthesis of protein markers of the differentiation of retinal neurons and pigment epithelium.
Results: There was positive clinical result after complex treatment including Retinalamin in all cases (improvement of visual acuity, peripheral field condition). Effect of Retinalamin treatment became apparent at the end of 1 month after treatment and even more evident after second course. Clinical effect was stable during half a year.
The aim of the study was to assess the efficiency of peptide bioregulators in patients with diabetic retinopathy (DR) after laser coagulation. Eighty patients (139 eyes) with preproliferative and proliferative stages of DR with ischemic diabetic maculopathy, with partial detachment of the posterior hyaloid membrane were studied. The age of the patients ranged 40 to 70 years (mean 59±3 years). Compensated type II diabetes mellitus, moderate form with duration of the disease 10-15 years was diagnosed in all the patients. Clinical observation of the patients before and after treatment included anamnesis, blood biochemistry lachrymal fluid, standard ophthalmologic examination, eye-ground checkup with a Goldman lens. All the patients (2-3 groups) underwent laser coagulation in ambulatory conditions. Operations were performed using laser argon ophthalmocoagulator “NOVUS 2000 Coherent Radiation” (USA) with wavelength, 154 nm. After laser coagulation the third group patients (n=30) additionally to conventional therapy received peptide bioregulator (Retinalamin – Gerofarm Company, Russia), 2.5 mg parabulbarly during 10 days. The remaining 20 patients (1 group) took only conventional treatment.
The paper presents the results of a clinical study of the therapeutic effect and safety of Retinalamin® medication in the treatment of complicated myopia. The medication was injected peribulbarly for a period of 10 days. A significant clinical effect of the medication for supporting therapy of moderate and high myopia has been shown. Retinalamin was shown to have a positive effect on the acuity and the quality of vision of myopic patients. The medication was well tolerated by the patients and caused no general or local allergic reactions. A statistically significant positive change of the major parameters of light sensitivity of the visual field was noted. The data of electrophysiological studies revealed a positive effect of retinalamin on the functional activity of the retina, especially in its central sections. The achieved effect was stable over the whole follow-up period (up to 3 months after the course of treatment).
The investigation, showed that combination therapy, including retinalamin, of 57 patients with post-inflammatory chorioretinal degeneration also slowed the progression of complicated cataract. This reduced the visual loss within the first year after treatment in 97,8% of cases, within two years in 95,6 % of cases, within three years in 66,7 % of cases, within four years in 53,3 % of cases.
In the dry form of age-related macular degeneration, the possibility of retinalamin treatment, as endonasal electrophoresis, is shown. The advantages of this method are stressed: noninvasiveness, absence of pain sensations, of allergic reactions, patients comfort. The treatment results were studied by objective and subjective methods. Two groups of patients were compared: 1 group subconjunctival injections, 2 group endonasal electrophoresis. In both groups, positive results are found.
Results and conclusion: First (main) group included 30 patients (60 eyes), in this group complex treatment with Retinalamin was prescribed. Second (control) group consisted of 30 patients (60 eyes), in this group patients were receiving Emoxipin. Retinalamin administration facilitated improvement of the main visual functions, electrophysiological and hemodynamic indices (decrease of linear velocity indices and resistance index).
Results: after Retinalamine administration clinically significant results were noted in 3, 6, 12 months (extending of the visual field boundaries, increasement of visual acuity, stabilization of the process according to ophthalmoscopy, increasement of the average thickness of retinal nerve fibers). At the end of the follow-up period in majority of patients of the control group we observed progression of POAG.
Conclusion: Retinalamin ca be recommended as effective and safety preparation for complex treatment of initial macular alteration.
Conclusion: Administration of Retinalamin leads to the improvement in optic nerve perfusion, ICA reactivity and electrophysiological parameters during three-month study.
Summary. A possibility for “Retinalamin” administration by means of endonasal electrophoresis in the dry form of AMD, is shown. Several advantages of this administration method are discussed: non-invasiveness, absence of pain, allergic reactions, comfort. Treatment results were studied by objective and subjective methods. 4 groups of patients were compared: 1st group — subconjunctival injections, 2nd group — endonasal electrophoresis, 3rd group (placebo) — physiotherapy (without electric current), 4th group — galvanization. In the 1st and 2nd groups, positive results were noted. In the 3rd group — data did not change. In the 4th group — small positive dynamics, in 1 month however the results returned to basline.
Summary. From 2005, an estimation of possible neuroprotective cytomedine Retinalamin action was carried out using objective investigation methods in patients with primary open-angle glaucoma stage 1 and 2 and in those with dry AMD, both being debilitating ophthalmic conditions.
Results: Combination of different treatment strategy of laser and conservative treatment was tested. The result has been designed for optimal balance improving performance and reducing ocular side effects. Retinalamin 5mg parabulbare number 10, Tanakan 1 tablet 3 times a day - 3 months. The optimal timing of re-treatment (at least 1 time in 9 months), in the case of significant progression of glaucomatious optic neuropathy - the timing is solved individually.
We studied the effect of retinal polypeptide Retinalamin on multipotent ectodermal cells of the early gastrula of Xenopus laevis. Neuronal differentiation of the early gastrula ectoderm including the brain, retina, and pigment epithelium depended on Retinalamin concentration.